Aligned Genetics

At a glance

Aligned Genetics filed 16 disclosures in the last 12 months, including 2 buyback and 1 insider. The most recent key filing was on Jun 26.

Revenue for 2025 was ₩16B, up 1.5% on 2024. Operating margin was 15.3% against 17.6% a year earlier. Debt was 56% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩8B and operating profit of ₩874.3M.

The 2025 annual report lists 66 employees with an average tenure of 3.9 years and average pay of ₩56.1M, #1165 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩116M each on average. It paid no cash dividend for 2025. 정연철 and related parties held 39.78% at year end.

From the 2025 annual report

Staff: 66 (40 men, 26 women), of whom 5 on fixed-term contracts. Total pay for the year: ₩3.9B. Directors and auditors: 6, paid ₩695M in total.

No cash dividend was paid for 2025.

Largest shareholder

정연철 holds 19.12%; with 8 related parties the group holds 39.78% of common shares at year end (from 39.91% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary